In solid cancers, hyperactivated PI3K/Akt/mTOR signaling is either due to activating mutations in EGFR, ERBB2, PIK3CA and Akt1, or loss of function of tumor suppressor genes such as PTEN [102]. This evidence concerns the gene AKT1 and neoplasm.